Fortress Biotech
Fortress Biotech

Fortress Biotech

Pharmaceuticals
WebsiteInvestor RelationsSEC
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology and therapeutics sectors.

$83.7M

Market Cap • 9/18/2026

2006

(20 years)

Founded

2011

(15 years ago)

IPO

NASDAQ

Listing Exchange

Flag of United States

United States

Country

Valuation

P/B

0,5

P/S

1,2

P/EBITDA

—

P/OCF

0,7

P/FCF

0,7

P/E

1

BVPS

5,3

EPS

2,6

Market Cap

Market Cap

83,7M

EV

-17,6M

EV/Revenue

-0,3

EV/EBITDA

0,8

EV/EBIT

0,6

Payout

Dividend Per Share

0

Dividend Yield

0%

Buyback Yield

-4%

Total Yield

-4%

Dividend Yield 5Y

1,2%

Payout

0%

Retained Earnings

-624,1M

Profitability

Gross Margin

65,6%

EBITDA Margin

—

EBIT Margin

—

Net Margin

206,2%

D&A/EBITDA

0%

R&D/Revenue

1,7%

Capex/Revenue

0%

Capex/D&A

0%

Capex/OCF

0%

SBC/OCF

8,2%

% PPE

4,3%

% Goodwill

0%

ROE

116%

ROIC

—

Growth

CAGR Revenue 5Y

5,4%

CAGR Op. Income 5Y

-24,7%

Leverage

N.D./EBITDA

6,3

Debt/Equity

0%

Current Ratio

4

Quick Ratio

3,8

Interest Coverage

—

Premium

Unlock 100% of the data and have immediate access on more than 6.000 companies with updated information!
  • Unrestricted access
  • Unlimited data history
  • Analysis videos
  • Quarterly highlights
  • Customizable financials table
  • Ranking
  • Discussions

...and much more!

Get Premium